Cudkowicz ME - Search Results

1

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis.

Cudkowicz ME, Shefner JM, Simpson E, Grasso D, Yu H, Zhang H, Shui A, Schoenfeld D, Brown RH, Wieland S, Barber JR; Northeast ALS Consortium. Cudkowicz ME, et al. Muscle Nerve. 2008 Jul;38(1):837-44. doi: 10.1002/mus.21059. Muscle Nerve. 2008. PMID: 18551622 Clinical Trial.

2

An update on superoxide dismutase 1 in familial amyotrophic lateral sclerosis.

Cudkowicz ME, Brown RH Jr. Cudkowicz ME, et al. J Neurol Sci. 1996 Aug;139 Suppl:10-5. doi: 10.1016/0022-510x(96)00084-6. J Neurol Sci. 1996. PMID: 8899652 Review. No abstract available.

3

Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis.

Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL, Schoenfeld DA, Hosler BA, Horvitz HR, Brown RH. Cudkowicz ME, et al. Ann Neurol. 1997 Feb;41(2):210-21. doi: 10.1002/ana.410410212. Ann Neurol. 1997. PMID: 9029070

4

Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic study.

Cudkowicz ME, Warren L, Francis JW, Lloyd KJ, Friedlander RM, Borges LF, Kassem N, Munsat TL, Brown RH Jr. Cudkowicz ME, et al. Neurology. 1997 Jul;49(1):213-22. doi: 10.1212/wnl.49.1.213. Neurology. 1997. PMID: 9222193 Clinical Trial.

5

Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene.

Cudkowicz ME, McKenna-Yasek D, Chen C, Hedley-Whyte ET, Brown RH Jr. Cudkowicz ME, et al. Ann Neurol. 1998 Jun;43(6):703-10. doi: 10.1002/ana.410430604. Ann Neurol. 1998. PMID: 9629839

6

Administration of nitric oxide synthase inhibitors does not alter disease course of amyotrophic lateral sclerosis SOD1 mutant transgenic mice.

Upton-Rice MN, Cudkowicz ME, Mathew RK, Reif D, Brown RH Jr. Upton-Rice MN, et al. Among authors: cudkowicz me. Ann Neurol. 1999 Mar;45(3):413-4. doi: 10.1002/1531-8249(199903)45:3<413::aid-ana24>3.0.co;2-5. Ann Neurol. 1999. PMID: 10072062 No abstract available.

7

The pharmacokinetics and pharmaco-dynamics of Procysteine in amyotrophic lateral sclerosis.

Cudkowicz ME, Sexton PM, Ellis T, Hayden DL, Gwilt PR, Whalen J, Brown RH Jr. Cudkowicz ME, et al. Neurology. 1999 Apr 22;52(7):1492-4. doi: 10.1212/wnl.52.7.1492. Neurology. 1999. PMID: 10227642 Clinical Trial.

8

Increased oxidative damage to DNA in ALS patients.

Bogdanov M, Brown RH, Matson W, Smart R, Hayden D, O'Donnell H, Flint Beal M, Cudkowicz M. Bogdanov M, et al. Free Radic Biol Med. 2000 Oct 1;29(7):652-8. doi: 10.1016/s0891-5849(00)00349-x. Free Radic Biol Med. 2000. PMID: 11033417

9

Effect of neurophilin ligands on motor units in mice with SOD1 ALS mutations.

Shefner JM, Brown RH Jr, Cole D, Chaturvedi P, Schoenfeld D, Pastuszak K, Matthews R, Upton-Rice M, Cudkowicz ME. Shefner JM, et al. Among authors: cudkowicz me. Neurology. 2001 Nov 27;57(10):1857-61. doi: 10.1212/wnl.57.10.1857. Neurology. 2001. PMID: 11723276

10

Comparison of incremental with multipoint MUNE methods in transgenic ALS mice.

Shefner JM, Cudkowicz ME, Brown RH Jr. Shefner JM, et al. Among authors: cudkowicz me. Muscle Nerve. 2002 Jan;25(1):39-42. doi: 10.1002/mus.10000. Muscle Nerve. 2002. PMID: 11754183

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

296 results

Search Page

Filters